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Background
Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of 
bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women 
with this disease.
Methods
We randomly assigned women with ovarian cancer to carboplatin (area under the 
curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 
3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body 
weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 addi-
tional cycles or until progression of disease. Outcome measures included progression-
free survival, first analyzed per protocol and then updated, and interim overall survival.
Results
A total of 1528 women from 11 countries were randomly assigned to one of the two 
treatment regimens. Their median age was 57 years; 90% had epithelial ovarian cancer, 
69% had a serous histologic type, 9% had high-risk early-stage disease, 30% were at 
high risk for progression, and 70% had stage IIIC or IV ovarian cancer. Progression-
free survival (restricted mean) at 36 months was 20.3 months with standard therapy, 
as compared with 21.8 months with standard therapy plus bevacizumab (hazard ratio 
for progression or death with bevacizumab added, 0.81; 95% confidence interval, 
0.70 to 0.94; P = 0.004 by the log-rank test). Nonproportional hazards were detected 
(i.e., the treatment effect was not consistent over time on the hazard function scale) 
(P<0.001), with a maximum effect at 12 months, coinciding with the end of planned 
bevacizumab treatment and diminishing by 24 months. Bevacizumab was associated 
with more toxic effects (most often hypertension of grade 2 or higher) (18%, vs. 2% 
with chemotherapy alone). In the updated analyses, progression-free survival (re-
stricted mean) at 42 months was 22.4 months without bevacizumab versus 24.1 months 
with bevacizumab (P = 0.04 by log-rank test); in patients at high risk for progression, 
the benefit was greater with bevacizumab than without it, with progression-free sur-
vival (restricted mean) at 42 months of 14.5 months with standard therapy alone and 
18.1 months with bevacizumab added, with respective median overall survival of 
28.8 and 36.6 months.
Conclusions
Bevacizumab improved progression-free survival in women with ovarian cancer. 
The benefits with respect to both progression-free and overall survival were greater 
among those at high risk for disease progression. (Funded by Roche and others; 
ICON7 Controlled-Trials.com number, ISRCTN91273375.)
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Ovarian cancer is the fourth most common cause of cancer-related deaths in women, with an estimated 200,000 cases 
and 125,000 deaths occurring annually worldwide. 
For the past decade, the standard treatment for 
women with advanced ovarian cancer has been 
surgery and platinum-based chemotherapy. At-
tempts to improve this standard two-drug che-
motherapy by adding a third cytotoxic drug failed 
to affect either progression-free survival or over-
all survival and resulted in an increase in toxic 
effects.1-4 Although intraperitoneal chemotherapy 
has extended overall survival by 12 to 17 months, 
it is an option only for women with advanced 
ovarian cancer who have a small amount of re-
sidual disease after surgery5-7 and is not widely 
used. Since the results of one trial suggested that 
weekly paclitaxel administration provided some 
benefit,8 trials are now under way to optimize 
carboplatin and paclitaxel scheduling.
Angiogenesis contributes to solid-tumor growth 
and metastasis.9,10 Epithelial ovarian-cancer cell 
lines frequently express vascular endothelial growth 
factor (VEGF).11 Decreased VEGF expression is 
associated with reductions in tumor vasculariza-
tion and angiogenesis and with prolonged sur-
vival.12 Bevacizumab (Avastin, Roche) is a mono-
clonal antibody that binds to all isoforms of the 
VEGF-receptor ligand VEGF-A, with evidence of 
efficacy in metastatic colorectal and lung can-
cers, as well as activity in renal, breast, and brain 
cancers.13-15 Phase 2 trials of bevacizumab in 
women with ovarian cancer have shown tumor 
responses and delayed disease progression.16-18
The Gynecologic Cancer InterGroup (GCIG) 
International Collaboration on Ovarian Neoplasms 
(ICON7) trial and the complementary Gyneco-
logic Oncology Group study 0218 (GOG-0218) 
(ClinicalTrials.gov number, NCT00262847) were 
designed to investigate the addition of bevaciz-
umab to standard chemotherapy in the first-line 
treatment of ovarian cancer. The results of the 
GOG-0218 study are reported elsewhere in this 
issue of the Journal by Burger et al.19
Me thods
Study Design and Conduct
ICON7 is led by the U.K. Medical Research Coun-
cil Clinical Trials Unit (MRC CTU) and was de-
signed by members of the Trial Management 
Group, who reviewed and approved the protocol. 
The Trial Management Group included represen-
tatives from GCIG and F. Hoffmann–La Roche. 
An independent international trial steering com-
mittee and an independent data and safety mon-
itoring committee provided oversight. Depend-
ing on national requirements, approval by ethics 
committees was obtained at each clinical site, 
nationally, or both. Data management was con-
ducted by independent contract research organi-
zations and MRC CTU (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org). Data analysis and interpreta-
tion and preparation of the manuscript were per-
formed independently by the funders and the 
sponsor (MRC). All authors had full access to all 
study data, had responsibility for the decision to 
submit the manuscript for publication, and 
vouch for the accuracy, integrity, and complete-
ness of the data as reported. The trial was con-
ducted in accordance with the protocol. (The 
protocol, including the statistical analysis plan, 
is available at NEJM.org.)
Eligibility Requirements
After surgery, women were eligible for enroll-
ment if they had histologically confirmed, high-
risk, early-stage disease (International Federation 
of Gynecology and Obstetrics [FIGO] stage I or IIA 
and clear-call or grade 3 tumors) or advanced 
(FIGO stage IIB to IV) epithelial ovarian cancer, 
primary peritoneal cancer, or fallopian-tube can-
cer (based on local histopathological findings). 
Additional eligibility criteria were an Eastern Coop-
erative Oncology Group (ECOG) performance sta-
tus of 0 to 2 (on a scale from 0 to 4, with 0 indicat-
ing normal activity, 1 symptomatic but ambulatory 
self-care possible, 2 ambulatory more than 50% 
of the time, 3 ambulatory 50% of the time or less 
and nursing care required, and 4 bedridden and 
possibly requiring hospitalization) and adequate 
coagulation values and bone marrow, liver, and 
renal function, with no plans for further sur-
gery before disease progression. All the patients 
provided written informed consent.
Randomization and Treatments
Randomization was performed centrally by an 
interactive telephone or Web-based system, with 
stratification according to GCIG group, FIGO stage 
and residual disease (i.e., FIGO stages I to III and 
≤1 cm of residual disease, stages I to III and >1 cm 
of residual disease, or stage III [inoperable] or IV), 
and planned interval between surgery and initi-
ation of chemotherapy (≤4 weeks or >4 weeks). 
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Enrollment of women with high-risk early-stage 
disease was restricted to 10% of the total study 
population.
Women were randomly assigned in a 1:1 ratio 
to receive carboplatin (area under the curve [AUC], 
5 or 6) and paclitaxel (175 mg per square meter of 
body-surface area), given every 3 weeks for 6 cycles 
(standard-chemotherapy group), or to the same 
regimen plus bevacizumab (7.5 mg per kilogram 
of body weight), given concurrently every 3 weeks 
for 5 or 6 cycles and continued for 12 additional 
cycles or until disease progression (bevacizum-
ab group). Bevacizumab was omitted at cycle 1 
to avoid delayed wound healing if chemotherapy 
was started within 4 weeks of surgery. Cycles of 
bevacizumab that were omitted for any reason 
were not replaced.
Assessments
Assessments were performed at the same time 
points in the two treatment groups. Clinical as-
sessments and cancer antigen 125 (CA-125) mea-
surements were performed before each cycle of 
chemotherapy, then every 6 weeks in year 1, every 
3 months during years 2 and 3, every 6 months 
during years 4 and 5, and then yearly. After dis-
ease progression, follow-up assessments were 
performed every 6 months for the first 5 years, 
then yearly. Computed tomography (CT) or mag-
netic resonance imaging (MRI) was performed 
at baseline, after chemotherapy cycles 3 and 6, 
at 9 and 12 months after randomization, every 
6 months in years 2 and 3, and then as clinically 
indicated until disease progression. All tumor 
assessments were reviewed by the principal in-
vestigator, who was unaware of treatment as-
signments. Quality of life was assessed with the 
use of the European Organization for Research 
and Treatment of Cancer (EORTC) QLQ-C30 and 
QLQ-OV28 questionnaires (see the Supplemen-
tary Appendix).
Outcome Measures
The principal outcomes of interest were progres-
sion-free survival and overall survival. Other out-
comes included biologic progression-free interval, 
response to therapy, toxicity, and quality of life.
Progression-free survival was calculated from 
the date of randomization to the date of the first 
indication of disease progression or death, which-
ever occurred first; the data for patients who 
were alive without disease progression were cen-
sored as of the date of their last assessment. 
Sensitivity analyses were performed in which 
data from patients who were alive without dis-
ease progression were censored at the date of the 
last imaging assessment. Disease progression was 
defined according to the Response Evaluation 
Criteria in Solid Tumors (RECIST)20 guidelines 
(see the Supplementary Appendix) on the basis of 
radiologic, clinical, or symptomatic indicators of 
progression and did not include isolated asymp-
tomatic progression on the basis of CA-125 levels. 
The biologic progression-free interval was calcu-
lated from the date of randomization to the date 
of the first CA-125–based progression21 or first 
RECIST–based progression, whichever occurred 
first (see the Supplementary Appendix). Overall 
survival was calculated from the date of ran-
domization to the date of death from any cause; 
data for patients still alive were censored at the 
date the patient was last known to be alive. Best 
overall response was assessed in patients with 
measurable disease at baseline who received at 
least one cycle of per-protocol treatment and was 
defined as the best confirmed response recorded 
from the start of treatment until 70 days after 
the last dose of per-protocol treatment.
Statistical Analysis
The primary analysis was carried out with the 
use of an unstratified log-rank test for the differ-
ence in the distribution of progression-free sur-
vival between the two groups. Other planned 
analyses included a log-rank test that stratified 
for factors used for randomization (excluding 
GCIG groups to limit the number of categories 
being tested); Cox regression analyses that ad-
justed for baseline covariates to assess the ro-
bustness of the result if the proportional-hazards 
assumption held; f lexible parametric survival 
models22 to smooth survival curves and estimate 
survival differences with the use of all survival 
data collected; and interaction analyses to ex-
plore the difference in the relative size of treat-
ment effects in subgroups classified according to 
baseline characteristics, high risk for progres-
sion (i.e., FIGO stage IV disease or FIGO stage III 
disease and >1.0 cm of residual disease after de-
bulking surgery), and stratification factors. All ef-
ficacy analyses for progression-free survival includ-
ed all patients who had been randomly assigned 
to treatment (i.e., the intention-to-treat popula-
tion). Safety analyses included patients who had 
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received at least one cycle of the assigned proto-
col treatment. All reported P values are two-sided, 
and all statistical analyses were performed at 
MRC CTU. The magnitude and timing of treat-
ment effect were explored with the use of hazard 
functions, including a formal test of the propor-
tional-hazards assumption.
With an estimated median progression-free 
survival of 18 months and median overall sur-
vival of 43 months in the standard-chemothera-
py group, the trial was designed to detect a 28% 
increase in median progression-free survival to 
23 months (hazard ratio, 0.78) and a 23% in-
crease in median overall survival to 53 months 
(hazard ratio, 0.81) in the bevacizumab group. 
At a 5% significance level and with 90% power 
for progression-free survival and 80% power for 
overall survival, a total of 684 progression-free 
survival events (i.e., disease progression or death) 
and 715 overall survival events were required. 
With 1520 women randomly assigned to treat-
ment over a period of 2 years, the required pro-
gression-free survival and overall survival events 
were expected to occur 1 and 3 years, respec-
tively, after entry of the last patient.
After submission of the primary analysis of the 
protocol-defined progression-free survival, regula-
tory authorities requested an overall survival analy-
sis with at least 365 deaths (50% of the required 
total number of deaths) and an update on pro-
gression-free survival with the use of the same 
data set.
R esult s
Patients
From December 2006 through February 2009, 
1528 women were enrolled at 263 centers in the 
United Kingdom, Germany, France, Canada, Aus-
tralia, New Zealand, Denmark, Finland, Norway, 
Sweden, and Spain. The cutoff date for the pri-
mary analysis was February 28, 2010, by which 
time a total of 759 progression-free survival events 
had been observed. The treatment groups were 
well balanced with respect to baseline character-
istics. The median age was 57 years, and 94% of 
the patients had an ECOG performance status of 
0 or 1; 90% had epithelial ovarian cancer; 9% had 
high-risk early-stage disease; 30% were at high 
risk for progression; 21% had FIGO stage III, 
IIIA, or IIIB disease; 70% had FIGO stage IIIC or 
IV disease; 69% had a serous histologic type; and 
26% had more than 1.0 cm of residual disease 
after surgical debulking (Table 1S in the Supple-
mentary Appendix).
Study Treatments Received
More than 90% of the women in both groups 
received 6 cycles of chemotherapy (91% in the 
standard-therapy group and 94% in the bevaci-
zumab group). Women in the bevacizumab group 
who started chemotherapy at or before 4 weeks 
after surgery received a median of 16 cycles (inter-
quartile range, 11 to 17) and those who started 
chemotherapy more than 4 weeks after surgery 
received a median of 17 cycles (interquartile range, 
12 to 18); 470 patients (62%) continued to receive 
bevacizumab through cycle 18, with 324 patients 
(42%) missing no infusions. In the standard-
therapy group, 1 patient received one dose of be-
vacizumab at cycle 1 in error. A total of 75 pa-
tients (5%) (48 in the standard-therapy group and 
27 in the bevacizumab group) received additional 
chemotherapy or bevacizumab before disease pro-
gression. After disease progression, a maximum 
of 44 patients (3%) (30 in the standard-therapy 
group and 14 in the bevacizumab group) may have 
received further antiangiogenic treatment; the ex-
act numbers are not known, since many patients 
are enrolled in blinded studies (Fig. 1).
Adverse Events
Five deaths related to treatment or to treatment 
and disease were reported: one in the standard-
therapy group (due to central nervous system 
ischemia) and four in the bevacizumab group 
(one each from gastrointestinal perforation, in-
tracerebral hemorrhage, recurrent bowel perfora-
tion and ovarian cancer, and neutropenic sepsis 
and ovarian cancer). Adverse events of grade 3 
or higher were reported in 56% of the women in 
the standard-therapy group and in 66% of the 
women in the bevacizumab group. Bevacizumab 
treatment appeared to be associated with an in-
crease in bleeding (mainly grade 1 mucocutane-
ous bleeding), hypertension of grade 2 or higher 
(18% with bevacizumab vs. 2% with standard 
therapy), thromboembolic events of grade 3 or 
higher (7% with bevacizumab vs. 3% with stan-
dard therapy), and gastrointestinal perforations 
(occurring in 10 patients in the bevacizumab group 
vs. 3 patients in the standard-therapy group) 
(Table 1). In the bevacizumab group, the percent-
age of patients in whom abscesses, fistulas, or 
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1528 Women were enrolled from 263 sites
in 11 countries
764 Were assigned to receive
standard chemotherapy
764 Were assigned to receive standard
chemotherapy plus bevacizumab therapy
696 (91%) Received 6 cycles of chemo-
therapy
11 Did not receive chemotherapy
2 Died
8 Withdrew consent
1 Had adverse event
57 Stopped chemotherapy early
22 Had adverse events or 
intercurrent illness
2 Died
16 Had insufficient therapeutic
response
2 Declined to participate
8 Withdrew consent
2 Had protocol violations
3 Had administrative or other
reasons
2 Had unknown reason
719 (94%) Received 6 cycles of chemo-
therapy
8 Did not receive chemotherapy
1 Had uncontrollable hyper-
tension
6 Withdrew consent
1 Had an adverse event
37 Stopped chemotherapy early
15 Had adverse events or 
intercurrent illness
1 Died
6 Had insufficient therapeutic
response
2 Declined to participate
6 Withdrew consent
2 Had protocol violations
3 Had administrative or other
reasons
2 Had unknown reason
48 Received additional chemotherapy
or bevacizumab before
progression
1 Received a single dose of beva-
cizumab in error
14 Received additional carboplatin
plus paclitaxel cycle (cycles 7–12)
10 Received minor modification 
of first-line chemotherapy
17 Received new line of chemo-
therapy
6 Have details of chemotherapy 
being queried
27 Received additional chemotherapy
or bevacizumab before
progression
3 Received additional bevacizu-
mab (cycle 19)
3 Received additional carboplatin
plus paclitaxel cycle (cycles 7–12)
4 Received minor modification 
of first-line chemotherapy
11 Received new line of chemo-
therapy
6 Have details of chemotherapy 
being queried
470 (62%) Received 18 cycles of 
bevacizumab
146 Missed one or more planned
doses
324 Did not miss any doses
2 Were still receiving treatment at
clinical cutoff
19 Did not receive bevacizumab
1 Died
8 Withdrew consent
1 Had uncontrollable hypertension
2 Had protocol violations
2 Had adverse events
1 Had delayed wound healing
4 Had unknown reasons
273 Stopped bevacizumab early 
(77 during chemotherapy, 196
 during maintenance phase)
112 Had adverse events or inter-
current illness
52 During chemotherapy phase
60 During maintenance phase
1 Died
104 Had insufficient therapeutic
response
19 Declined to participate
11 Withdrew consent
19 Had administrative or other
reasons
7 Had unknown reason
Patient status at clinical cutoff: 
111 (15%) Died
2 (<1%) Alive on treatment
625 (82%) Alive in follow-up
26 (3%) Alive, but withdrew consent
Patient status at clinical cutoff:
130 (17%) Died
0 (0%) Alive on treatment
604 (79%) Alive in follow-up
30 (4%) Alive, but withdrew consent
Figure 1. Randomization and Outcomes.
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gastrointestinal perforations developed was simi-
lar in the group that received bevacizumab with 
their first cycle of chemotherapy and in the group 
that did not (3% [19 of 611] and 4% [6 of 135], 
respectively).
Best Overall Response
The rate of complete or partial remission was 
48% in the standard-therapy group and 67% in 
the bevacizumab group — a difference of 19 per-
centage points (95% confidence interval [CI], 11 
to 28; P<0.001) (Table 2S in the Supplementary 
Appendix).
Progression-Free Survival
With a median follow-up of 19.4 months, disease 
progression or death occurred in 759 patients 
(392 in the standard-therapy group and 367 in the 
bevacizumab group). The median progression-
free survival was 17.3 months in the standard-
therapy group and 19.0 months in the bevacizu-
mab group. A comparison of Kaplan–Meier curves 
for progression-free survival showed a signifi-
cant difference between the two groups (esti-
mated hazard ratio for progression or death in 
the bevacizumab group, 0.81; 95% CI, 0.70 to 0.94; 
P = 0.004) (Fig. 2A). There was clear evidence of 
nonproportional hazards (test of proportional 
hazards, P<0.001). The effect of bevacizumab 
changed over time (Fig. 2B) and was maximal at 
12 months, with an improvement in progression-
free survival at this time of 15.1% (95% CI, 10.7 
to 19.5) as compared with standard therapy; 
thereafter, the effect was diminished so that pro-
gression-free survival was slightly higher in the 
standard-therapy group at 24 months. In detecting 
nonproportional hazards, the log-rank test re-
mains useful, but the conventional hazard ratio 
is not meaningful; a better estimate of treatment 
effect is provided by the restricted mean differ-
ence (the difference in areas under the whole 
length of the progression-free survival curves). The 
restricted mean values for progression-free survival 
in the standard-therapy and bevacizu mab groups, 
estimated with the use of all data obtained up 
to 36 months after randomization, were 20.3 
months and 21.8 months, respectively — a differ-
ence of 1.5 months (95% CI, 0.1 to 2.9). Sensitivity 
analyses censoring data obtained at the last ra-
diologic tumor assessment led to similar conclu-
sions (Fig. 1S, Panel a, in the Supplementary Ap-
pendix) (hazard ratio for progression or death in 
the bevacizumab group, 0.79; 95% CI, 0.68 to 
0.91; P = 0.001 by the log-rank test [nonpropor-
tional hazards detected]; restricted mean differ-
ence, 1.2 months [progression-free survival of 17.8 
months with standard therapy vs. 19.0 months 
with bevacizumab], estimated at 30 months after 
randomization).
Among patients at high risk for progression 
(Fig. 2C), the estimated median progression-free 
survival was 10.5 months with standard therapy, 
as compared with 15.9 months with bevacizumab 
(hazard ratio for progression or death in the be-
vacizumab group, 0.68; 95% CI, 0.55 to 0.85; 
P<0.001). The restricted mean values at 36 months 
were 13.1 months with standard therapy and 
16.5 months with bevacizumab.
Isolated CA-125–based progression occurred in 
254 women (117 in the standard-therapy group and 
137 in the bevacizumab group). Disease progres-
sion as assessed on the basis of CA-125, RECIST, or 
both occurred in 767 women (395 in the standard-
therapy group and 372 in the bevacizumab group). 
The hazard ratio for biologic progression-free 
survival with bevacizumab, as compared with 
standard therapy, was 0.83 (95% CI, 0.72 to 0.96; 
P = 0.009) (Fig. 1S, Panel b, in the Supplementary 
Appendix).
Exploratory analyses of potential interactions 
are summarized in Figure 3, and in Figure 3S in 
the Supplementary Appendix. There is a sugges-
tion of a greater benefit with bevacizumab in 
women with a worse ECOG performance score 
than for those with a normal performance score 
(P = 0.02 for interaction).
Overall Survival and Quality of Life
Overall survival data are not final; the final results 
are due in 2013 (Fig. 2D). There were 241 deaths: 
231 (96%) were disease-related (128 in the standard-
therapy group and 103 in the bevacizumab 
group), 5 were treatment-related, and 5 were due 
to other causes (see the Supplementary Appen-
dix). Both groups showed improvement in glob-
al quality of life over time; although differences 
between the two groups were consistently pres-
ent, these were small and not considered to be 
clinically significant (i.e., there was less than a 
10-point difference) (Fig. 3S and Table 3S in the 
Supplementary Appendix).
Updated Analyses
The cutoff date for updated analyses of progression-
free survival and overall survival was November 30, 
2010, after a median follow-up period of 28 months 
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Table 1. Summary of Adverse Events.*
Adverse Events
Standard Chemotherapy
(N = 753)
Bevacizumab
(N = 745)
number of patients (percent)
Any event
None 3 (<1) 0
Grade 1 or 2 331 (44) 254 (34)
Grade 3 or 4 410 (54) 483 (65)
Grade 5 9 (1) 8 (1)
Any bleeding
None 666 (88) 450 (60)
Grade 1 or 2 85 (11) 286 (38)
Grade ≥3 2 (<1) 9 (1)
Bleeding other than mucocutaneous, tumor-associated,  
or within CNS
None 712 (95) 688 (92)
Grade 1 or 2 39 (5) 55 (7)
Grade ≥3 2 (<1) 2 (<1)
Mucocutaneous bleeding
None 698 (93) 469 (63)
Grade 1 or 2 55 (7) 271 (36)
Grade ≥3 0 5 (1)
Tumor-associated bleeding 0 0
Bleeding within CNS
None 753 (100) 743 (99)
Grade 1 or 2 0 0
Grade ≥3 0 2 (<1)
Abscess and fistula
None 743 (99) 732 (98)
Grade 1 or 2 3 (<1) 7 (1)
Grade ≥3 7 (1) 6 (1)
Gastrointestinal perforation
None 750 (99) 735 (99)
Grade 1 or 2 0 0
Grade ≥3 3 (<1) 10 (1)
Hypertension
None 706 (94) 552 (74)
Grade 1 31 (4) 57 (8)
Grade 2 14 (2) 90 (12)
Grade ≥3 2 (<1) 46 (6)
Proteinuria
None 734 (97) 712 (96)
Grade 1 or 2 18 (2) 29 (4)
Grade ≥3 1 (<1) 4 (1)
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Table 1. (Continued.)
Adverse Events
Standard Chemotherapy
(N = 753)
Bevacizumab
(N = 745)
number of patients (percent)
Any thromboembolic event
None 708 (94) 665 (89)
Grade 1 or 2 22 (3) 29 (4)
Grade ≥3 23 (3) 51 (7)
Venous thromboembolic event
None 722 (96) 695 (93)
Grade 1 or 2 18 (2) 18 (2)
Grade ≥3 13 (2) 32 (4)
Arterial thromboembolic event
None 742 (99) 718 (96)
Grade 1 or 2 1 (<1) 7 (1)
Grade ≥3 10 (1) 20 (3)
Local thrombosis
None 750 (99) 740 (99)
Grade 1 or 2 3 (<1) 5 (1)
Grade ≥3 0 0
Neutropenia
None 534 (71) 534 (72)
Grade 1 or 2 105 (14) 88 (12)
Grade ≥3 114 (15) 123 (17)
Febrile neutropenia
None 738 (98) 724 (97)
Grade 1 or 2 1 (<1) 2 (<1)
Grade ≥3 14 (2) 19 (3)
Thrombocytopenia
None 684 (91) 652 (88)
Grade 1 or 2 54 (7) 67 (9)
Grade ≥3 15 (2) 26 (3)
Reversible posterior leukoencephalopathy syndrome 0 0
Congestive heart failure
None 750 (99) 742 (99)
Grade 1 or 2 0 1 (<1)
Grade ≥3 3 (<1) 2 (<1)
Complication of wound healing
None 737 (98) 708 (95)
Grade 1 or 2 13 (2) 27 (4)
Grade ≥3 3 (<1) 10 (1)
Hyperbilirubinemia
None 753 (100) 742 (99)
Grade 1 or 2 0 2 (<1)
Grade ≥3 0 0
* CNS denotes central nervous system.
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and a total of 378 deaths observed. Table 2 shows 
the results of the primary and updated analyses for 
progression-free survival and overall survival.
Progression-free Survival
A total of 934 progression-free survival events 
(progression or death) were reported (464 in the 
standard-therapy group and 470 in the bevacizu-
mab group). Results were very similar to those of 
the primary analysis, again showing clear evidence 
of a nonproportional hazard (P = 0.001) (Table 2, 
and Fig. 5S, Panel a, in the Supplementary Appen-
dix). A long-term improvement in progression-free 
survival was seen with bevacizumab, as compared 
with standard therapy, with median durations of 
19.8 months in the bevacizumab group and 17.4 
months in the standard-therapy group, and cor-
responding restricted means of 24.1 months and 
22.4 months at 42 months (hazard ratio for pro-
gression or death in the bevacizumab group, 
0.87; 95% CI, 0.77 to 0.99; P = 0.04).
The test for interaction suggests that the size 
of the effect of bevacizumab differed between 
patients at high risk for progression and the 
rest of the study population (P = 0.06) (Fig. 4S, 
Panels a and b, in the Supplementary Appendix). 
Among the 465 women at high-risk for pro-
gression, 386 (83%) had disease progression or 
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Figure 2. Progression-free Survival and Overall Survival Curves.
Panel A shows differences in progression-free survival according to treatment group in the total study population. Kaplan–Meier curves (and 
smoothed curves) in Panel B show the difference in progression-free survival between the standard-therapy group and the bevacizumab group, 
along with 95% confidence intervals; the red horizontal line represents zero effect (i.e., no treatment difference). The red horizontal line indi-
cates no difference. Panel C shows progression-free survival, according to treatment group in patients at high risk for progression. Panel D 
shows overall survival according to treatment group.
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died, and the benefit with respect to progression-
free survival was greater with bevacizumab than 
with standard therapy, with median durations of 
10.5 months in the standard-therapy group and 
16.0 months in the bevacizumab group and re-
stricted means of 14.5 months and 18.1 months 
at 42 months in the two groups, respectively 
(hazard ratio for progression or death in the 
bevacizumab group, 0.73; 95% CI, 0.60 to 0.93; 
P = 0.002). The updated progression-free survival 
curves were similar to those obtained in the 
primary analyses up to 24 months of follow-up 
(Fig. 3B).
Overall Survival
A total of 146 new deaths (all disease-related) 
were reported, making the total number of deaths 
378 (200 in the standard-therapy group and 178 in 
the bevacizumab group). In contrast to the data 
for progression-free survival, there was no evi-
dence of nonproportional hazards. A comparison 
of the Kaplan–Meier curves resulted in a hazard 
ratio for death in the bevacizumab group of 0.85 
(95% CI, 0.69 to 1.04; P = 0.11). The early indica-
tion of a trend toward improved overall survival 
with bevacizumab has not changed (Fig. 3C).
The test for interaction suggests that the size 
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Figure 3. Updated Progression-free Survival and Overall Survival Curves.
Updated data on progression-free survival are shown according to treatment group in the total study population (Panel A) and in patients 
at high risk for progression (Panel B). Updated data on overall survival are shown according to treatment group in the total study popu-
lation (Panel C) and in patients at high risk for progression (Panel D).
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Table 2. Results of Primary and Updated Analyses of Progression-free Survival and Overall Survival with Standard 
Chemotherapy Alone versus Standard Therapy plus Bevacizumab.*
Variable Primary Analysis Updated Analysis
Standard 
Chemotherapy Bevacizumab
Standard 
Chemotherapy Bevacizumab
Progression-free survival
All patients
No. of events 392 367 464 470
Median (mo) 17.3 19.0 17.4 19.8
Hazard ratio (95% CI) 0.81 (0.70–0.94) 0.87 (0.77–0.99)
P value† 0.004 0.04
P value‡ <0.001 <0.001
Restricted mean (mo)
At 36 mo 20.3 21.8 20.6 22.5
At 42 mo NA NA 22.4 24.1
Patients at high risk for progression§
No. of progression-free survival 
events
158 173 196 190
Median (mo) 10.5 15.9 10.5 16.0
Hazard ratio (95% CI) 0.68 (0.55–0.85) 0.73(0.60–0.93)
P value† <0.001 0.002
P value‡ <0.001 <0.001
Restricted mean (mo)
At 36 mo 13.1 16.5 14.1 17.6
At 42 mo NA NA 14.5 18.1
Overall survival¶
All patients
No. of events 130 111 200 178
Median (mo) Not yet reached Not yet reached Not yet reached Not yet reached
1-year survival, per Kaplan–Meier 
 estimates (%)
93 95 86 92
Hazard ratio (95% CI) 0.81 (0.63–1.04) 0.85 (0.69–1.04)
P value† 0.098 0.11
Patients at high risk for progression§ No analyses 
 performed
No analyses 
 performed
No. of events 109 79
Median (mo) 28.8 36.6
Hazard ratio (95% CI) 0.64 (0.48–0.85)
P value† 0.002
* The cutoff dates for the initial and updated data analyses were February 28, 2010, and November 30, 2010, respectively, 
and the respective median follow-up periods were 19 months and 28 months. CI denotes confidence interval.
† P values were obtained with the use of the unadjusted log-rank test.
‡ P values were obtained with the use of the test based on Schoenfeld residuals for the proportional-hazards assumption.
§ There were 465 patients in this group.
¶ There were 1528 patients in this group.
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of the effect of bevacizumab on overall survival 
differs between the patients at high risk for 
progression and the rest of the women studied 
(P = 0.011) (Fig. 4S, Panels c and d, in the Supple-
mentary Appendix). Among the women at high 
risk for progression, there were 188 deaths (109 in 
the standard-therapy group and 79 in the bevaciz-
umab group) (Fig. 3D, and Fig. 4S, Panel d, in the 
Supplementary Appendix). The median overall sur-
vival is 28.8 months in the standard-therapy group 
and 36.6 months in the bevacizumab group, 
(hazard ratio for death in the bevacizumab 
group, 0.64; 95% CI, 0.48 to 0.85; P = 0.002).
Discussion
The use of bevacizumab (7.5 mg per kilogram) 
given concurrently with 5 or 6 cycles of platinum-
based chemotherapy and continued for an addi-
tional 12 cycles improved progression-free surviv-
al by about 2 months and increased the response 
rate by 20%. These data provide clear evidence of 
the biologic activity of bevacizumab, with a max-
imum improvement in progression-free survival 
of approximately 15% at 12 months, which dis-
appeared by 24 months. The restricted mean dif-
ference summarized the treatment effect for the 
nonproportional hazards detected and showed an 
improvement in the mean progression-free sur-
vival of 1.5 to 2 months with bevacizumab. The 
progression-free survival and overall survival ben-
efits were much greater among the patients at 
high risk for progression (improvements of 3.6 
months [restricted mean] and 7.8 months [me-
dian], respectively) than among patients at lower 
risk. Both the timing of the maximal treatment 
effect, which coincided with the end of planned 
bevacizumab treatment (and was achieved in more 
than 70% of the women), and the larger treatment 
effect observed in women with more advanced 
disease, who were more likely to receive bevaciz-
umab up to the time of disease progression, are 
intriguing and raise the possibility that pro-
longed therapy beyond 12 months, perhaps un-
til disease progression, might further improve 
the outcome.
Treatment with bevacizumab did not affect the 
delivery of chemotherapy. However, bevacizumab 
did expand the range of toxic effects, including 
hypertension and bowel perforation.
As compared with the GOG-0218 study, the 
ICON7 study enrolled patients with advanced-
stage cancer with no visible residual disease, as 
well as some with high-risk early-stage disease; 
in the ICON7 study, half the dose of bevaciz-
umab was used (7.5 mg per kilogram, vs. 15 mg 
per kilogram in the GOG-0218 study) for a shorter 
maintenance period (12 cycles, vs. 16 cycles in the 
GOG-0218 study). The dose of bevacizumab used 
in the ICON7 study is one of the licensed doses 
for metastatic colorectal cancer but is half the 
licensed dose for metastatic breast cancer. The 
prognosis for patients at high risk for progres-
sion in the ICON7 study was similar to that for 
patients in the GOG-0218 study, with median 
progression-free survival of 10.5 months in the 
standard-therapy group. A 3.6-month (restricted 
mean) improvement in progression-free survival 
was observed with bevacizumab, similar to that 
seen in the GOG-0218 study.19
For the whole ICON7 patient population, the 
overall magnitude of the benefit with respect to 
progression-free survival was relatively modest af-
ter the addition of bevacizumab to platinum-based 
chemotherapy and maintenance bevacizumab for 
the 12-cycle extension after chemotherapy was 
completed. Some will argue that final overall 
survival data are needed before the results can 
be fully interpreted. The apparently greater effect 
of bevacizumab in patients with a poor prognosis 
is encouraging. Final results for overall survival 
rates should be available in 2013.
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